Table 1 Characteristics of the study subjects
Characteristic | Total cohort | Subgroup* |
|---|---|---|
Number of subjects (male) | 333 | 174 |
Age (y), mean ± SD | 68.6 ± 10.4 | 67.1 ± 10.9 |
Comorbidity, n (%) | 229 (68.8) | 116 (66.7) |
Comorbid diseases, n (%) | Â | Â |
 1. Hypertension | 110 (33.0) | 61 (35.1) |
 2. Neuropsychiatric | 58 (17.4) | 28 (16.1) |
 3. Cardiac | 52 (15.6) | 20 (11.5) |
 4. Endocrine/metabolic | 51 (15.3) | 22 (12.6) |
 5. Respiratory | 35 (10.5) | 16 (9.2) |
 6. Malignancy | 23 (6.9) | 12 (6.9) |
 7. Chronic kidney disease | 22 (6.6) | 10 (5.7) |
 8. Hepatobiliary | 21 (6.3) | 15 (8.6) |
 9. Rheumatoid arthritis | 17 (5.1) | 14 (8.0) |
Fracture history, n (%) | 301 (90.4) | 151 (86.8) |
Fracture sites, n (%) | Â | Â |
 Spine | 265 (79.6) | 134 (77.0) |
 Hip | 48 (14.4) | 21 (12.1) |
 Others@ | 21 (6.3) | 8 (4.6) |
Baseline DXA, n (%) | 94 (28.2) | 60 (34.5) |
BMD T-score (SD), mean ± SEM |  |  |
 Spine | −2.0 ± 0.2 | −1.9 ± 0.2 |
 Femoral neck | −2.1 ± 0.1 | −1.9 ± 0.1 |
 Total hip | −1.7 ± 0.1 | −1.6 ± 0.2 |
First prescriber, n (%) | Â | Â |
 Rheumatology | 140 (42.0) | 85 (48.9) |
 Orthopedics | 101 (30.3) | 37 (21.3) |
 Others# | 92 (27.6) | 52 (29.9) |
Enrolment criteria | Â | Â |
 NOF recommendation, n (%) | 282 (84.7) | 144 (82.8) |
 ACR guideline, n (%) | 51 (15.3) | 30 (17.2) |
Vertebroplasty, n (%) | 11 (3.3) | 6 (3.4) |
Tobacco use | 1 (0.3) | 0 (0) |
Alcohol use | 2 (0.6) | 1 (0.6) |